Pharma’s Bedtime Horror Stories: Gene Therapy, Digital Revolution, Pricing ‘Fixes’
Regulators, industry executives, and patient advocates are losing sleep due to a host of concerns and anxieties, including the need for evolving regulatory paradigms, patients’ ability to access life-changing medicines, and the pace of digital change.
You may also be interested in...
The SARS-CoV-2 outbreak has the federal government working not only on a vaccine candidate specifically targeted at the novel coronavirus but also thinking more broadly about ways to head off future potential pandemics with emerging pathogens.
US FDA will survey health care providers’ current understanding of analgesic abuse-deterrent formulations and conduct an experimental study exploring the effectiveness of different terminology and descriptions for such products; agency has heard complaints from its own AdComms about terminology around abuse deterrence.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.